Advised pharmaceutical firm on aggressive growth strategy

Convinced the board of a leading pharmaceuticals company that its approach to a material but non-core asset was depleting value; advocated for a “split” of the business to pursue an aggressive growth strategy as the higher value option to both the current path and sale.

Related capabilities